The purpose of this study is to determine if, after receiving nine cycles of the usual treatment with three drugs (daratumumab, lenalidomide, and dexamethasone), adding bortezomib to the three drugs for the second set of nine treatment cycles (cycles 10-18) could be more effective in shrinking your cancer or preventing it from returning, compared to continuing on the same three-drug combination for another nine treatment cycles.
Learn more about the ECOG-ACRIN EAA181 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
